AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology

• Five posters presented by Innate Pharma and collaborators;
• New data further supporting the rationale of four of Innate's clinical and preclinical programs;
• New checkpoint inhibitor program targeting CD73 strengthens Innate's positioning in targeting the tumor microenvironment.

MARSEILLE, France, March 17, 2016 -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) announces today that new preclinical data will be presented at the American Association Of Cancer Research (AACR) Annual Meeting 2016 taking place from 16 to 20 April 2016, in New Orleans, Louisiana, USA.

These data supports the rationale of four of Innate's clinical and preclinical programs:

 -  One poster will present preclinical data supporting the rationale for combining an NKG2A checkpoint inhibitor with a PD-1 or a PD-L1 checkpoint inhibitor in mouse models;

 -  One poster will present new data reinforcing the rationale for IPH4301, a first-in-class anti-MICA/B humanized antibody;

 -  Three posters will present preclinical data on new discovery programs targeting CD73 and CD39, immune checkpoints regulating the adenosine pathway, including one poster reporting data generated by OREGA Biotech, Innate's collaborator on the CD39 project.

Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, said: "The AACR annual meeting is one of the major events in our field. This year, we are proud to present 5 posters, demonstrating the progress of our pipeline and the excellence of Innate Pharma's science. These data support the rationale and the potential of our assets, and strengthen Innate's unique positioning in the immuno-oncology field".

Beyond posters presentations, Innate Pharma's team will be present with a booth (#2604) to receive its peers and the financial community at AACR.

Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will hold a conference call to the attention of analysts and portfolio managers to discuss the data published and Company's innovative pipeline.

Time and dial in: Tuesday, April 19^th 10:30am Eastern Time
USA: 888 504 7963
International: +1 719 325 2452
Access code: 1890466

About the posters to be presented at the AACR Annual Meeting 2016:

• IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer
  • Permanent Abstract Number: 1491
  • Session Category: Immunology
  • Session Title: Immune Modulating Agents and Therapeutic Antibodies
  • Session Date and Time: Monday Apr 18, 2016 8:00 AM - 12:00 PM
  • Location: Convention Center, Halls G-J, Poster Section 25
  • Presented by Mathieu Bléry, PhD
• NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model
  • Permanent Abstract Number: 2342 
  • Session Category: Immunology
  • Session Title: Immune Checkpoints 1
  • Session Date and Time: Monday Apr 18, 2016 1:00 PM - 5:00 PM
  • Location: Convention Center, Halls G-J, Poster Section 26
  • Presented by Pascale André, PhD
• Discovery and characterization of new original blocking antibodies targeting the CD73 immune checkpoint for cancer immunotherapy
  • Permanent Abstract Number: 2344  
  • Session Category: Immunology
  • Session Title: Immune Checkpoints 1
  • Session Date and Time: Monday Apr 18, 2016 1:00 PM - 5:00 PM
  • Location: Convention Center, Halls G-J, Poster Section 26

                   Presented by Ivan Perrot, PhD

• Disruption of the CD39 immune checkpoint pathway increases the efficacy of various anticancer therapies in syngeneic mouse models 
  • Permanent Abstract Number: 3218
  • Session Category: Immunology
  • Session Title: Immune Checkpoints 2
  • Session Date and Time: Tuesday Apr 19, 2016 8:00 AM - 12:00 PM
  • Location: Convention Center, Halls G-J, Poster Section 25
  • Presented by Jérémy Bastid, PharmD, PhD (OREGA Biotech)
• Preclinical development of a humanized blocking antibody targeting the CD39 immune checkpoint for cancer immunotherapy
  • Permanent Abstract Number: 3222  
  • Session Category: Immunology
  • Session Title: Immune Checkpoints 2
  • Session Date and Time: Tuesday Apr 19, 2016 8:00 AM - 12:00 PM
  • Location: Convention Center, Halls G-J, Poster Section 25
  • Presented by Ivan Perrot, PhD

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

The Company has three clinical-stage programs, including two checkpoint inhibitors in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.

Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and AstraZeneca, Sanofi and Novo Nordisk A/S.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 118 employees as at December 31, 2015.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

PR in English http://hugin.info/155662/R/1995151/734915.pdf

HUG#1995151